Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team
16 June 2017 - 10:01PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced additions
to the Board of Directors and senior management team:
- Keith L. Brownlie was elected to the Company’s Board of
Directors at Celldex’s 2017 Annual Meeting of Stockholders held
yesterday. Mr. Brownlie was employed by the accounting firm
Ernst & Young LLP from 1974 to 2010, where he served as audit
partner for numerous public companies and was the Life Sciences
Industry Leader for the New York metropolitan area.
- Sam Martin has been promoted to Senior Vice President and Chief
Financial Officer, effective July 1, 2017. Mr. Martin joined
Celldex in April 2009 and currently serves as Vice President,
Finance. As previously announced, Mr. Martin will assume the
responsibilities of Avery “Chip” Catlin, who is retiring on June
30, 2017.
- Sarah Cavanaugh has been promoted to Senior Vice President,
Corporate Affairs and Administration. Ms. Cavanaugh joined Celldex
in August 2012 as Vice President of Investor Relations and
Corporate Communications. She will continue fulfilling those
responsibilities and will assume leadership for human resources,
employee relations, organizational development and internal
communications.
"Keith brings an exceptional background in finance and
accounting within the life sciences industry,” said Larry
Ellberger, Chairman of the Board of Directors at Celldex
Therapeutics. "We believe he will be a valuable addition to the
Board of Directors as a whole, and in particular, to the audit
committee, which he will chair."
“Sam’s expertise in corporate finance and established leadership
at Celldex over the last eight years has been critical to the
organization. His knowledge of our business has ensured a smooth
transition with Chip’s pending retirement,” said Anthony Marucci,
Co-founder, President and Chief Executive Officer of Celldex
Therapeutics. “For five years, Sarah has led our investor relations
group and provided communications counsel throughout the company.
During that time, she has played an increasing role in
organizational development and will be instrumental in ensuring
that we further strengthen the culture of Celldex and develop our
people. I look forward to continuing to work with them both in
their new capacities.”
Mr. Brownlie retired from Ernst & Young in 2010. He
currently serves as a member of the boards of directors and
chairman of the audit committees for two publicly-held
biopharmaceutical companies—Soligenix, Inc. and RXi Pharmaceuticals
Corporation, and he previously served in the same capacity for the
publicly-held EpiCept Corporation and Cancer Genetics, Inc. Mr.
Brownlie received a B.S. in Accounting from Lehigh University and
is a Certified Public Accountant.
Mr. Martin joined Celldex as the Director of Financial
Reporting, Planning and Analysis in April 2009 and has held roles
of increasing responsibility and leadership. Prior to joining
Celldex, Mr. Martin served as the Director of Finance and Corporate
Compliance for Alseres Pharmaceuticals, Inc., where he was
responsible for managing the financial and SEC reporting and the
annual budget and planning process. Mr. Martin began his career at
Ernst & Young LLP, holding various positions prior to
completing his tenure as Audit Manager, where he provided audit,
review, due diligence and consulting services to public and private
companies in the biotechnology, medical device, health care, high
technology, manufacturing and consumer product industries. Mr.
Martin received an M.B.A. from Boston University, a B.S. from
Skidmore College and is a Certified Public Accountant.
Prior to joining Celldex, Ms. Cavanaugh served from 2007 to 2012
as a Vice President at MacDougall Biomedical Communications, a
strategic communications and investor relations firm for the life
sciences industry, where she developed and implemented programs for
more than 20 biopharmaceutical companies and served as the in-house
oncology expert. Ms. Cavanaugh has served in a number of leadership
positions in the health care and life sciences industry, including
Director of Corporate Communications for Point Therapeutics, an
oncology-focused biotech company, and Director of Corporate
Communications for Fallon Community Health Plan, a leading
Massachusetts managed care organization. She began her health care
career at the American Cancer Society, holding various positions
providing leadership in physician education, corporate
communications, government relations and marketing. She completed
her tenure there as Division Communications and Marketing Director
for the Mid-South Division, where she was responsible for managing
the efforts of marketing and communications staff across six
states. Throughout her career, Ms. Cavanaugh has played a
leadership role in organizational development and employee
relations/communication. Ms. Cavanaugh received her B.A. from the
University of New Hampshire.
About Celldex Therapeutics, Inc.Celldex is
developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline is
built from a proprietary portfolio of antibodies and
immunomodulators used alone and in strategic combinations to create
novel, disease-specific therapies that induce, enhance or suppress
the body's immune response. Visit www.celldex.com.
Forward Looking StatementThis release contains
"forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These statements are typically preceded by words such as
"believes," "expects," "anticipates," "intends," "will," "may,"
"should," or similar expressions. These forward-looking statements
reflect management's current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct or that those goals will be
achieved, and you should be aware that actual results could differ
materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to
successfully integrate the business and programs of Kolltan with
our business and programs; our ability to successfully complete
research and further development and commercialization of
glembatumumab vedotin and other Company drug candidates; our
ability to obtain additional capital to meet our long-term
liquidity needs on acceptable terms, or at all, including the
additional capital which will be necessary to complete the clinical
trials that we have initiated or plan to initiate; the
uncertainties inherent in clinical testing and accruing patients
for clinical trials; our limited experience in bringing programs
through Phase 3 clinical trials; our ability to manage and
successfully complete multiple clinical trials and the research and
development efforts for our multiple products at varying stages of
development; the availability, cost, delivery and quality of
clinical and commercial grade materials produced by our own
manufacturing facility or supplied by contract manufacturers, who
may be our sole source of supply; the timing, cost and uncertainty
of obtaining regulatory approvals; our ability to maintain and
derive benefit from the Fast Track designation for glembatumumab
vedotin which does not change the standards for regulatory approval
or guarantee regulatory approval on an expedited basis, or at all;
the failure of the market for the Company's programs to continue to
develop; our ability to protect the Company's intellectual
property; the loss of any executive officers or key personnel or
consultants; competition; changes in the regulatory landscape or
the imposition of regulations that affect the Company's products;
and other factors listed under "Risk Factors" in our annual report
on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs and Administration
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Charles Liles
Associate Director, Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
cliles@celldex.com
Media Contact
Dan Budwick
Founder, 1AB Media
(973) 271-6085
dan@1abmedia.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024